Kubesova, B <br/><br/>
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.  [electronic resource] 

 -  Leukemia  02 2018 
 - 450-461 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2017.230  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Alleles<br/>Disease Progression<br/>Female<br/>Gene Frequency--drug effects<br/>High-Throughput Nucleotide Sequencing--methods<br/>Humans<br/>Hydroxyurea--administration & dosage<br/>Janus Kinase 2--genetics<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation--drug effects<br/>Myeloproliferative Disorders--drug therapy<br/>Retrospective Studies<br/>Tumor Suppressor Protein p53--genetics<br/>Young Adult